Jennifer Burstein
Director/Board Member at STOKE THERAPEUTICS, INC.
Net worth: - $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ian Smith | M | 58 | 14 years | |
| Josh Bilenker | M | 52 |
Treeline Biosciences, Inc.
 Treeline Biosciences, Inc. BiotechnologyHealth Technology Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation. | - |
| Adrian Krainer | M | 65 | 10 years | |
| Seth Harrison | M | 63 | 9 years | |
| David Bonita | M | 48 |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation. | 5 years |
| John Kelley | M | 70 | 16 years | |
| Kerry Clem | M | 54 | 13 years | |
| Huw Nash | M | 57 | 10 years | |
| Arthur Levin | M | 70 | 9 years | |
| Isabel Aznarez | M | 52 | 10 years | |
| Arthur Tzianabos | M | 60 | 6 years | |
| Julie Smith | F | 53 | 4 years | |
| Garry Menzel | M | 59 | 4 years | |
| Jonathan Allan | M | - | - | |
| Edward Kaye | M | 75 | 7 years | |
| Peder K. Jensen | M | 69 | 13 years | |
| Doug Snow | M | - | 3 years | |
| Jeffrey Engelman | M | - |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation. | - |
| Sunitha Ramamurthy | F | - | 6 years | |
| Barry Ticho | M | 64 | 7 years | |
| Stephen Tulipano | M | 65 | 5 years | |
| Steven Elms | M | 60 |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation. | - |
| Shamim Ruff | F | 64 | 6 years | |
| Avi Z. Naider | M | 52 |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation. | - |
| Dawn Kalmar | F | 47 | 5 years | |
| Eric Rojas | M | - | - | |
| Aftab Kherani | M | 50 |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation. | - |
| Kristina Burow | F | 50 |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation. | - |
| David Schenkein | M | 66 |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation. | - |
| Joan Wood | F | - | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dov Goldstein | M | 56 | 2 years | |
| Jeff Randall | M | 80 | 17 years | |
| David Guyer | M | 64 |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 5 years |
| Robert Morales | M | 57 | 7 years | |
| Lauren Sabella | F | 63 | 12 years | |
| Paul Chaney | M | 66 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 10 years |
| Christian Richardson | M | - | - | |
| Adrian L. Rabinowicz | M | - | 6 years | |
| Nancy M. Wyant | F | - | 5 years | |
| Michael Barrett | M | 81 | 2 years | |
| Marty Glick | M | 74 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | - |
| Kent Rogers | M | 54 | - | |
| Steven Harr | M | 53 | 3 years | |
| Barry Greene | M | 60 | 14 years | |
| Tim Mayleben | M | 63 | 4 years | |
| Robin A. Walker | M | 55 | 1 years | |
| Brian Walter | M | - | - | |
| Christopher Pierce | M | 44 | 2 years | |
| Michelle Huie | F | - | - | |
| Brian W. Hutchinson | M | - | 5 years | |
| Bonnie M. Pappacena | F | - | - | |
| Thomas C. Aquilina | M | - | - | |
| Jennifer Low | M | 54 | 2 years | |
| Todd F. Baumgartner | M | - | 5 years | |
| Rebecca R. Levine | F | - | 5 years | |
| Erin Campany | F | 57 | 4 years | |
| S. Michael Rothenberg | M | - | 5 years | |
| Elizabeth Keating | F | - | - | |
| Michael Samar | M | 51 | 3 years | |
| Gene Liau | M | 69 | 4 years | |
| Charles R. Allerson | M | 56 | 2 years | |
| Meena | M | 51 | 4 years | |
| Deborah Morosini | M | 65 | 3 years | |
| Soon H. Lee | M | - | - | |
| Enrique Carrazana | M | 62 | 5 years | |
| Martin Freed | M | 63 | 1 years | |
| Enrique Dilone | M | 57 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 4 years |
| Michael Rogers | M | 64 | 3 years | |
| Glenn Sblendorio | M | 68 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 3 years |
| Mary Fisher | F | 62 | 7 years | |
| Wise Young | M | 74 | 16 years | |
| Clare M. Carmichael | F | 64 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 2 years |
| Emmett Cunningham | M | 63 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 4 years |
| Loni da Silva | F | - |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 5 years |
| Richard Batycky | M | 56 | - | |
| Sam Hall | M | 42 | 5 years | |
| Katie Cairati | F | - | - | |
| Thomas C. Wessel | M | 68 | 3 years | |
| Barrett Katz | M | 74 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 2 years |
| Herbert Raymond Henney | M | - | 9 years | |
| Evelyn Harrison | F | - |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 6 years |
| Ruhi Khan | F | - | 5 years | |
| Christopher Carroll | M | 57 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 1 years |
| Joseph T. Kennedy | M | 56 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 2 years |
| Douglas Kargman | M | - | - | |
| Andrew Hindman | M | 51 | 5 years | |
| Keith Westby | M | 49 |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 87 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jennifer Burstein
- Personal Network
